ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
MOUNTAIN VIEW, Calif., June 27, 2011 /PRNewswire/ -- ChemoCentryx, Inc. today announced that the Company's novel CCR2 antagonist significantly improves kidney function and hyperglycemia in experimental models. These data implicate CCR2-driven processes in the pathology of type 2 diabetes and associated complications such as diabetic nephropathy. Results were highlighted in a poster presentation entitled "CCR2 Antagonism Improves Renal Function and Hyperglycemia in Preclinical Models of Type 2 Diabetes" at the 71st Scientific Session of the American Diabetes Association held in San Diego. CCX140, the Company's lead novel, orally available CCR2 antagonist, successfully met its primary endpoint of safety and tolerability in a Phase II clinical trial in type 2 diabetes, while demonstrating clinical activity on glycemic indices following only 28 days of treatment. CCX140 is currently poised to enter Phase II clinical development for the treatment of diabetic nephropathy.
"In the United States there are more than 31 million patients living with chronic kidney disease, 37% as a result of having diabetes," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Complicating matters further is the fact that the current standard of care does not stop or reverse progression and with the increasing number of patients who progress to end-stage renal disease each year -- there is a clear demand for better treatment options. We believe these data demonstrate compelling rationale to move forward CCX140, our most advanced CCR2 antagonist, in a Phase II clinical trial for the treatment of diabetic nephropathy."
CCR2 inhibition was studied in two models of type 2 diabetes: diet-induced obese mice and db/db mice. Treatment with the CCR2 antagonist significantly improved multiple metabolic/renal parameters in obese, diabetic mice, including hyperglycemia, insulin sensitivity, serum adiponec